ArticleFrontiers in pharmacology2021
Anti-Adipogenic Effect of
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Astragalin: A promising herbal compound with broad anticancer potential (Review).Oncology letters · 2026Review
- Antihyperglycemic Activity ofMolecules (Basel, Switzerland) · 2025Article
- Promising pancreatic lipase inhibitory activity of a novel tetrapeptide isolated from endophytic Fusarium incarnatum.World journal of microbiology & biotechnology · 2025Article
- Harnessing the Power ofMolecules (Basel, Switzerland) · 2025Review
- Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions.International journal of obesity (2005) · 2025Review
- Article
- Natural bioactive compounds and their mechanisms of action in the management of obesity: a narrative review.Frontiers in nutrition · 2025Review
- Deficiency of SDHC promotes metastasis by reprogramming fatty acid metabolism in colorectal cancer.Journal of translational medicine · 2024Article
- Screening and identification of lncRNAs in preadipocyte differentiation in sheep.Scientific reports · 2024Article
- Antiobesity Drug Discovery Research:Current drug targets · 2024Review
- Natural products as novel anti-obesity agents: insights into mechanisms of action and potential for therapeutic management.Frontiers in pharmacology · 2023Review
- Modulation of Cytoskeleton, Protein Trafficking, and Signaling Pathways by Metabolites fromPharmaceuticals (Basel, Switzerland) · 2022Review
- Article
- Signaling pathways in obesity: mechanisms and therapeutic interventions.Signal transduction and targeted therapy · 2022Review
- Derhamnosylmaysin Inhibits Adipogenesis via Inhibiting Expression of PPARγ and C/EBPα in 3T3-L1 Cells.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a persistent and continuously expanding social health concern. Excessive fat mass accumulation is associated with increased risk of chronic diseases including diabetes, atherosclerosis, non-alcoholic steatohepatitis, reproductive dysfunctions and certain types of cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.